发布于 2017年07月22日
抗逆转录病毒药物是治疗蒙受HIV病毒传染的病人的一线药物。然而，相对付未传染的小我私家而言，传染上HIV病毒的小我私家接管抗逆转录病毒药物治疗后仍然有较高的灭亡率。在传染进程中，HIV病毒传染者发生炎症而导致被称作肠黏膜的肠道壁受损，从而答允肠道细菌逃离出来和进入血液中而导致全身传染。肠黏膜的康健明显性地受到肠道中的细菌群体的影响，，并且有越来越多的证据证实增补有益于患有诸如肠道易激综合症、艰巨梭菌传染和炎症性肠病之类的肠道疾病的病人。
在一项新的研究中，益生菌，来自美国美国过敏症与熏染病研究所的Jason
Brenchley和同事们证实增补益生菌大概也有益于颠末抗逆转录病毒药物治疗的HIV病毒传染者。Brenchley和同事们只操作抗逆转录病毒药物可能连系利用抗逆转录病毒药物和多种益生菌来治疗传染上个SIV的猕猴(人HIV传染的模式动物)。相对付只接管抗逆转录病毒药物治疗的猕猴而言，接管连系治疗的猕猴拥有增强的胃肠道免疫成果和低落的炎症。
相关研究功效于2013年1月16日颁发在Journal of Clinical
Investigation期刊上，论文标题为"Probiotic/prebiotic supplementation of
antiretrovirals improves gastrointestinal immunity in SIV-infected
macaques"。
DOIdoi:10.1172/JCI66227
PMC:
PMID:
Probiotic/prebiotic supplementation of antiretrovirals improves
gastrointestinal immunity in SIV-infected macaques
Nichole R. Klatt1, Lauren A. Canary1, Xiaoyong Sun2, Carol L.
Vinton1, Nicholas T. Funderburg3, David R. Morcock4, Mariam
Quiñones1, Clayton B. Deming5, Molly Perkins1, Daria J. Hazuda6,
Michael D. Miller7, Michael M. Lederman3, Julie A. Segre5, Jeffrey
D. Lifson4, Elias K. Haddad2, Jacob D. Estes4 and Jason M.
Brenchley1
HIV infection results in gastrointestinal (GI) tract damage, microbial translocation, and immune activation, which are not completely ameliorated with suppression of viremia by antiretroviral (ARV) therapy. Furthermore, increased morbidity and mortality of ARV-treated HIV-infected individuals is associated with these dysfunctions. Thus, to enhance GI tract physiology, we treated SIV-infected pigtail macaques with ARVs, probiotics, and prebiotics or with ARVs alone. This synbiotic treatment resulted in increased frequency and functionality of GI tract APCs, enhanced reconstitution and functionality of CD4+ T cells, and reduced fibrosis of lymphoid follicles in the colon. Thus, ARV synbiotic supplementation in HIV-infected individuals may improve GI tract immunity and thereby mitigate inflammatory sequelae, ultimately improving prognosis.
文章转载自：***/***